MLAB - mesalabs.com Operating income before deduction of amortization

Graphic logo of mesalabs.com (MLAB)

Mesa Laboratories, Inc. (MLAB) relies on the stable profitability of niche consumables, as confirmed by the overall chart on GURU.Markets. The EBITDA shows that the current value is 49.26. Growth is driven by the acquisition of filtration system developers and synergies with pharmaceutical plants. However, asset integration challenges and strict regulatory oversight create risks of margin compression.

MLAB Mesa Laboratories Corp. Operating profit before deduction of amortization (11/23/2025 - 11/12/2026)

Mesa Labs (MLAB) - metric breakdowns and financial figures

- current price and projected stock value:
Price Mesa Laboratories Corp.|MLAB - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Mesa Labs|MLAB - Enterprise Value
- balance sheet equity data:
Accounting Value per Share Mesa Labs|MLAB - Company Net Assets|Market Value to Book Value mesalabs.com|MLAB - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio Mesa Laboratories, Inc.|MLAB - Long-Term Debt to Capital|Current Liabilities to Capital Mesa Laboratories Inc|MLAB - Company Aggregate Debts|Debt to Book Value Ratio Mesa Labs|MLAB - Company Long-Term Debts|Short-Term Debt Volume Mesa Labs|Quick Liquidity Indicator mesalabs.com
- earnings and multiples data:
MLAB - Net Profit|Projected Future Earnings Mesa Laboratories, Inc.|MLAB - Price to Earnings Ratio|Future Price to Earnings mesalabs.com|MLAB - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Mesa Labs|MLAB - Operating profit EBITDA|Net earnings per one share for the last twelve months Mesa Labs|MLAB - Earnings per share for the last twelve months|Net earnings per share growth for the trailing year mesalabs.com|MLAB - Net earnings per share growth this year|Earnings growth forecast for next year Mesa Laboratories, Inc.
Summary company analytics:Mesa Laboratories Corp. - MLAB
Mass-produced product of Mesa Laboratories, Inc.

This indicator aggregates net operating cash flow before taxes and interest obligations, allowing investors to assess the real liquidity of Mesa Laboratories, Inc. (MLAB) during periods of market volatility. The effectiveness of the "Mesa Way" strategy to optimize margins for niche biopharma assets is directly reflected in the recorded EBITDA level, signaling the company's ability to act as a cash generator for further expansion.

Who Mesa Laboratories, Inc. competes with

Company profit before taxes, interest and amortization ABT (Abbott Corp.)|Thermo Fisher Scientific - Operating profit EBITDA|Operating income before deduction of amortization gehealthcare.com GEHC|MTD: Operating profit EBITDA|Operating profit before deduction of amortization Waters Corp|Operating profit before deduction of amortization TECH|BRKR: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Azenta, Inc. (AZTA)|Operating profit before deduction of amortization vareximaging.com VREX|Operating profit EBITDA SMLR (Semler Scientific)|Butterfly Network Inc (BFLY) - Profit before interest, taxes and amortization|Quantum-Si Corp - Operating profit EBITDA|NNOX (Nano-X Imaging Ltd) - Operating profit before amortization|QTRX: Operating profit EBITDA|MASS - Operating income before deduction of amortization|CV (CapsoVision, Inc.) - Operating profit EBITDA|Operating profit before deduction of amortization MaxCyte Inc. (MXCT)|Operating profit EBITDA RPID|Operating profit EBITDA Seer Bio (SEER)|Profit before payment of interest, taxes and amortization Hyperfine, Inc. HYPR|fonar.com - Profit before payment of interest, taxes and amortization|DXR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization MDAI (spectral-ai.com)|VIVS: Operating profit EBITDA|Profit before interest, taxes and amortization Aclarion Corporation (ACON)|Profit before payment of interest, taxes and amortization Akoya Biosciences Inc|THMO - Operating profit before depreciation charges|Operating profit before deduction of amortization TLIS (Talis Biomedical)|Operating profit EBITDA T2 Biosystems Inc. (TTOO)